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Abstract
Different institutions recognized that antimicrobial resistance is a global health 
threat that has compounded by the reduction in the discovery and development 
of new antimicrobial agents. Therefore, the development of new antimicrobial 
therapeutic strategies requires immediate attention to avoid the 10 million deaths 
predicted to occur by 2050 as a result of multidrug-resistant (MDR) bacteria. 
Despite the great interest in the development of repurposing drugs, only few 
repurposing drugs are under clinical development against Gram-negative critical-
priority pathogens. In this chapter, we aim: (i) to discuss the therapeutic potential 
of the repurposing drugs for treating MDR bacterial infections, (ii) to summarize 
their mechanism of action, and (iii) to provide an overview for their preclinical and 
clinical development against these critical-priority pathogens.
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1. Introduction
Antimicrobial resistance poses a well-recognized global health threat due to 
the global dissemination of bacteria resistants to multiple antibiotic classes. This 
situation is deemed a global priority by the World Health Organization and the 
European Centre for Disease Prevention and Control [1, 2]. Currently, global 
deaths due to antimicrobial resistance are more than 70,000 in USA and in Europe 
together [3, 4]. Therefore, the development of new antimicrobial therapeutic strat-
egies requires immediate attention to avoid the high number of deaths predicted 
to occur in the future as a result of multidrug-resistant (MDR) bacteria [5]. It is 
clear that effective solutions such as the establishment of antimicrobial stewardship 
programs to optimize the use of existing antibiotics, the promotion of novel rapid 
diagnostics to curtail the unnecessary use of antimicrobial agents; the promotion, 
development, and use of vaccines and novel antibiotic classes are urgently needed 
[5]. However, the increased prevalence of infections by MDR bacteria and the 
scarcity of novel antibiotic families that are under clinical development could war-
rant the development of new antimicrobial therapeutic strategies for use alone or 
together with one of the scarce but clinically relevant antibiotics.
Repurposing drugs have been gained renewed interest in the last decade as 
reflected by several recent studies [6–9]. Since then, 4% of the 407 preclinical 
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antibiotic projects from 314 institutions are related with repurposing drugs evalu-
ated against bacterial infections [10]. Further evidence of the increased interest 
in these drugs class is that the development process for repurposed drugs benefits 
from a large body of available knowledge and reduces the time and cost of develop-
ment [9]. The majority of repurposed drugs developed to treat bacterial infections 
are approved or in advanced clinical stages as anticancer drugs, anti-inflammatory/
immunomodulatory drugs, antipsychotic and antidepressant drugs, statins and 
iron-storage drugs [9]. The large difference between the numerous drugs approved 
or in development for oncologic indications and the small number of new anti-
biotics is surprising given that over the past decades antimicrobial resistance has 
emerged as an important public health with high associated mortality, and in 
2050 antimicrobial resistance would result in 10 million more deaths than those 
caused by cancers [5]. Although multiple factors contribute to the scarcity of new 
antibiotics for bacterial infections, the success of repurposing drugs-based antibi-
otic therapy as an alternative approach can be reached. Repurposing drugs-based 
approaches could provide a viable alternative for the treatment of certain MDR 
bacterial infections. This could be especially important for certain infections caused 
by MDR Gram-negative infections such as Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacterales carbapenems-resistants, for which current antimi-
crobial treatments are not active. The WHO has classified as critical priority these 
pathogens for research and development of new antibiotics [1].
In this chapter, we focus on the current state of knowledge regarding the potential 
benefits and disadvantages of repurposing drugs treatments for MDR Gram-negative 
infections. We outline the advances to-date in their preclinical and clinical develop-
ment as antimicrobial agents. To this end, we introduce in Pubmed database different 
key words such as repurposing drug, repositioning, antimicrobial and/or antibacte-
rial in order to find published literature about the repurposing drugs for treatment of 
bacterial infections.
2. Therapeutic potential of repurposing drugs
There is a widely acknowledged that repurposing drugs could address the 
global increase in antimicrobial resistance and especially the treatment of MDR 
Gram-negative bacteria. This could be due by the fact that repurposing drugs might 
exhibit some advantageous characteristics. Repurposing drugs target some genes 
and surface proteins that are not targets of currently used antimicrobials [9]. Of 
note, it is unlikely that their antibacterial activities can be disturbed by existing 
antimicrobial resistance mechanisms. The most of repurposing drugs increased the 
permeability and damaged the bacterial membrane without killing the bacteria. 
They enhanced the activity of the current antibiotics [9]. Furthermore, repurposing 
drugs are drugs approved by the Federal Drug Administration (FDA), information 
about their pharmacological characteristics (both safety and pharmacokinetic) in 
preclinical and clinical trials is widely available. Therefore, the time and economic 
costs associated with the repurposing of these drugs for other therapeutic applica-
tions such as the treatment of bacterial infections will be minimized [11]. Finally, 
to our knowledge, it was not reported that repurposing drugs produce selective 
pressure on the human microbiome.
Substantial progress has been made in the development of repurposed drugs 
against bacterial infections. Although some current compounds in the pipeline have 
exhibited promising results, existing pharmacokinetic characteristics limits the 
activity of many of them. It should be taken into account in the preclinical devel-
opment of repurposing drugs the possible need for new formulations to increase 
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their bioavailability and absorption. This aspect is relevant for the development of 
anthelmintics. Extensive binding to plasma proteins has been reported for oxyclo-
zanide and other salicylanilides, which currently limits their systemic and intrave-
nous applications [12]. Of note, positive results have been seen with niclosamide 
derivative O-alkylamino-tethered, which has a potent antibacterial effect against 
carbapenemase producing and colistin resistant Enterobacterales isolates [13]. 
Inhalable nanosuspension and salt form of niclosamide, niclosamide ethanolamine, 
have presented better solubility profile and inhibited the P. aeruginosa quorum 
sensing (QS) [14, 15]. An additional relevant issue should be taken into account is 
that their administration route can be changed. ADMET tests should be performed 
before the development of these repurposing drugs in clinical trials. The choice of 
the route is a relevant aspect in serious infections in hospitalized patients such as 
ventilated-associated pneumonia who patients are intubated and other circum-
stances in which the oral route is not available.
3.  Mechanisms of action of repurposing drugs against Gram-negative 
bacilli
Different agents are promising both in vitro and in vivo candidates to be repo-
sitioned as antimicrobial agents to treat infections caused by MDR Gram-negative 
bacilli. A variety of drugs with different mechanisms of action and targets have 
been selected including: DNA, RNA and proteins inhibitors [16–20], QS regulators 
[15, 17, 21–25], biofilm formation inhibitors and disruptors [26, 27], drugs that 
interact with cell membrane [28–30], drugs that interact with iron metabolism 
[31–35], and host immune system modulators [36–39]. These drugs and their 
mechanisms of action against critical-priority pathogens (A. baumannii, P. aerugi-
nosa and Enterobacterales) are summarized in Figure 1 and Table 1.
3.1 DNA, RNA and proteins inhibitors
Anticancer and anti-inflammatory drugs that interact with DNA, RNA and 
proteins have been reported. Mitomycin C, used in several types of carcinomas such 
Figure 1. 
Mechanisms of action of repurposed drugs against Gram-negative critical-priority pathogens.
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Bacterial target Repurposed 
drug
Clinical 
indications
Mechanism of action Reference
DNA, RNA & proteins Mitomycin c Superficial 
vesical 
carcinoma
Binding to DNA during DNA synthesis and causes inhibition of its synthesis and function in 
P. aeruginosa and E. coli
[18]
Cisplatin Cancer Upregulation of the recA gene of P. aeruginosa, which is known to be important for DNA 
repair
[20]
Celecoxib Inflammation Inhibition of RNA, DNA, and protein synthesis in S. aureus [19]
Quorum sensing 5-fluorouracil Solid tumors Inhibition of QS formation in P. aeruginosa [23, 41]
Raloxifene Breast cancer Binding to PhzB2 which is involved in the production of pyocyanin, a pigment related with 
virulence factor and QS signalling molecule in P. aeruginosa
[24]
Niclosamide Helminthiasis Production of the QS signaling molecules N-3-oxododecanoyl-homeserine lactone and N- 
butanoyl-homoserine lactone in P. aeruginosa
[15, 25]
Meloxicam Inflammation Interaction with active sites of the QS of P. aeruginosa [26]
Metformin Diabetes Inhibition of QS system by bind to LasR by hydrogen bonding and electrostatic interaction 
and to rhlR by hydrogen bonding in P. aeruginosa
[21]
Biofilm formation 5-Fluorouracil Solid tumors Regulation of different genes involved in the biofilm formation by P. aeruginosa [41]
Meloxicam Inflammation Decrease in the extracellular Psl, Pel, and alginate production by P. aeruginosa [26, 27]
Glatiramer 
acetate
Inflammation Disruption of the biofilm formation by GNB [42]
Azathioprine Crohn’s disease Inhibition of WspR, involved in the regulation of c-di-GMP known as a regulator of the 
bacterial biofilm formation by P. aeruginosa and E. coli
[43]
Ebselen Bipolar disorder 
and ischemic 
stroke
Inhibition of c-di-GMP in P. aeruginosa [44, 45]
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Bacterial target Repurposed 
drug
Clinical 
indications
Mechanism of action Reference
Cell membrane Niclosamide Helminthiasis Increase of the negative surface charge of A. baumannii and K. pneumoniae [30]
Oxyclozanide Helminthiasis Reduction of the membrane potential and increase of aminoglucosides accumulation in P. 
aeruginosa. Increase of the membrane permeability of A. baumannii, P. aeruginosa and K. 
pneumoniae
[28, 47]
Rafoxanide Helminthiasis Increase of the negative surface charge of A. baumannii and K. pneumoniae
Increase of the membrane permeability of A. baumannii, P. aeruginosa and K. pneumoniae
[46]
Ivermectin Helminthiasis Increase of the membrane permeability of A. baumannii, P. aeruginosa and K. pneumoniae [48]
Mitotane Cancer Permeabilization of the outer membrane of A. baumannii, P. aeruginosa and K. pneumoniae [49]
Pentamidine Protozoal 
infection
Alteration of the outer membrane of GNB, due to the interaction with membrane 
lipopolysaccharides
[29]
Robenidine Protozoal 
infection
Alteration of the cell membrane of GNB [50]
Ebselen Bipolar disorder 
and ischemic 
stroke
Inhibition of the TonB-mediated physiology of A. baumannii and E. coli [51]
Iron metabolism Gallium Nitrate Lymphoma and 
bladder cancer
Interferance with iron-dependent metabolic pathways in GNB [31–33]
Ebselen Bipolar disorder 
and ischemic 
stroke
linhibition of TonB involved in iron acquisition by A. baumannii and E. coli [51]
Host immune system Tamoxifen Breast cancer Reduction in the migration of immune cells from bone marrow to blood through the 
reduction of MCP-1 and IL-18 in presence of A. baumannii, P. aeruginosa and E. coli
[36]
Calcitriol Enhancement of the killing activity of monocytes and macrophages towards P. aeruginosa. [37]
GTS-21 Inflammation Enhancement of the macrophage function towards P. aeruginosa via inhibiting the release of 
nuclear protein high mobility group box-1
Reduction of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) release
[38, 39]
Table 1. 
Repurposing drugs and their mechanisms of action.
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as the superficial vesical carcinoma [40], has shown activity against A. baumannii, 
P. aeruginosa and E. coli in vitro and in vivo [16–18]. Mitomycin C binds to DNA 
during DNA synthesis and causes inhibition of its synthesis and function in P. aeru-
ginosa and E. coli [18]. Cisplatin, approved for treatment of a number of cancers, 
was found to inhibit microbial cells growth [17, 20]. The mechanism of action of 
this drug has been attributed to the upregulation of the recA gene in P. aeruginosa, 
which is important for DNA repair, implicating that cisplatin could interfere with 
DNA replication [20]. Moreover, celecoxib, a non-steroidal anti-inflammatory drug 
(NSAID), has been tested in a Caenorhabditis elegans and in whole-animal  
A. baumannii and P. aeruginosa infection models. It was suggested that inhibit dose-
dependently the DNA, RNA and protein synthesis as in Staphylococcus aureus [19].
3.2 Quorum sensing regulators
QS inhibition and regulation have been reported as antibacterial properties of 
anticancer, anthelminthic, anti-inflammatory and hypoglycemic drugs such as 
5-fluorouracil, raloxifene, niclosamide, meloxicam and metformin. 5-fluorouracil 
is a potent drug indicated for the treatment of different types of solid tumors, that 
has shown antibacterial activity in vitro [17, 22, 23]. The antibacterial mechanism of 
this drug has been proposed as QS inhibitor [23, 41]. Also, 5-fluorouracil has dual 
inhibition mechanisms including functioning as an alternative substrate resulting 
in miscoding DNA and RNA, and inhibiting thymidylate synthase [22]. Moreover, 
the selective estrogen receptor modulator (SERM) raloxifene, used in the preven-
tion of osteoporosis and invasive breast cancer in post-menopausal women, has 
presented activity against Gram-negative bacilli (GNB). Raloxifene binds to PhzB2 
which is involved in the production of pyocyanin, a pigment related with both the 
virulence factor and the QS signaling molecule in P. aeruginosa [24]. Regarding the 
anthelmintic drugs, niclosamide, used for the treatment of helminthiasis, has been 
reported to inhibit QS in P. aeruginosa in Galleria mellonella model by hindering the 
cell’s response and production of the QS signaling molecules as N-3-oxododecanoyl-
homeserine lactone and N-butanoyl-homoserine lactone [15, 25]. Finally, meloxi-
cam, a NSAID used to manage moderate-to-severe pain, and metformin, one of 
the most commonly prescribed oral hypoglycemic for treatment of type 2 diabetes, 
have been reported to interact with active sites and to inhibit the QS of P. aeruginosa, 
respectively [21, 26, 27]. Molecular docking study has shown that metformin could 
bind to LasR by hydrogen bonding and electrostatic interaction and to rhlR by 
hydrogen bonding only [21].
3.3 Biofilm formation inhibitors and disruptors
Compared with QS, much less drugs have been act on the biofilm formation. 
5-fluorouracil has been revealed to regulate different genes involved in the biofilm 
formation by P. aeruginosa [41]. More specifically, meloxicam has been reported to 
inhibit biofilm formation of P. aeruginosa by decreasing the extracellular Psl, Pel 
and alginate production, three vital biofilm exopolysaccharides in this pathogen 
[26, 27]. Moreover, glatiramer acetate, a drug used in the treatment of multiple 
sclerosis, has also been shown to disrupt biofilm formation by GNB [42]. Finally, 
azathioprine, an immunosuppressive drug used for the treatment of Crohn’s 
disease and other autoimmune diseases, has exhibited anti-biofilm activity against 
P. aeruginosa and E. coli through the inhibition of WspR [43]. WspR is a diguanyl-
ate cyclase involved in the regulation of a signal molecule called cyclic-di-GMP 
(c-di-GMP) known as a regulator of the bacterial biofilm formation [43]. The 
same mechanism of action has been used by ebselen to exhibit anti-biofilm activity 
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against P. aeruginosa [44, 45]. Ebselen, despite the fact that it is not an FDA-
approved drug, it is being investigated in clinical trials for the treatment of bipolar 
disorder, hearing loss and tinnitus and ischemic stroke.
3.4 Interaction with cell membrane
Various anthelmintic, anticancer and antiprotozoal drugs such as niclosamide, 
oxyclozanide, rafoxanide, ivermectin, mitotane, pentamidine and robenidine have 
been reported to interact with the bacterial cell membrane. Three anthelmintic drugs 
in combination with colistin have shown activity against GNB by the regulation of 
electric charges. Niclosamide and rafoxanide were discovered to increase the negative 
surface charge of bacterial membrane in A. baumannii and K. pneumoniae clinical 
strains in vitro [30, 46]. In turn, oxyclozanide has enhanced the activity of additional 
tobramycin against P. aeruginosa by reducing the membrane potential and increasing 
tobramycin accumulation [28]. This increase in the negative surface charges allow to 
restore the activity of colistin in colistin-resistant (Col-R) A. baumannii and K. pneu-
moniae, and the activity tobramycin in tobramycin-resistant P. aeruginosa [30, 46]. 
Not only the regulation of electric charges has been reported as mechanism of action 
of anthelmintic drugs, but the increase of bacterial membrane permeabilization 
has also been reported. Oxyclozanide, rafoxanide and ivermectin have been shown 
to increase the membrane permeability of A. baumannii, P. aeruginosa and K. pneu-
moniae, especially in Col-R strains [46–48]. Moreover, Tran et al. have demonstrated 
that mitotane, a FDA-approved antineoplastic drug, in combination of polymyxin B 
lead mitotane to enter inside A. baumannii, P. aeruginosa and K. pneumoniae through 
the permeabilization of the outer membrane by polymyxin B [49]. Additionally, 
antiprotozoal drugs, pentamidine and robenidine, possess a mechanism of action 
that disturbs the outer membrane of GNB, due to the interaction with membrane 
lipopolysaccharides (LPS) [29, 50]. Finally, ebselen has also presented antibacterial 
effect against A. baumannii and E. coli by inhibiting the TonB-mediated physiology, 
which is involved in iron acquisition from host sources [51].
3.5 Interaction with iron metabolism
Antunes et al. have demonstrated that virulent bacteria are able to acquire iron 
in the blood and tissues [33]. Given the essential role of iron in bacterial physiology 
and pathogenicity, iron uptake and metabolism have become attractive targets for 
the development of new antibacterial agents [52, 53]. The ion gallium [Ga(III)], a 
ferric iron [Fe(III)] mimetic, has been shown to inhibit the growth of many bacterial 
species by interfering with iron-dependent metabolic pathways. Therefore, gallium 
drugs have gained special interest in the fight of MDR-GNB infections [31]. Gallium 
nitrate is an anticancer drug that was approved by the FDA for the treatment of 
cancer-associated hypercalcemia. Antibacterial properties of gallium nitrate have 
been previously reported against GNB infections, both in vitro and in vivo [31–35].  
In addition, Ebselen as mentioned before has the characteristic to inhibit TonB in  
A. baumannii and E. coli [51].
3.6 Host immune system modulators
Also, some drugs that modulate host immune system have reported antibacterial 
activity against GNB. Tamoxifen, a SERM used for breast cancer treatment, can 
reduced the migration of immune cells from bone marrow to blood through the 
reduction of monocytes chemoattractant protein 1 (MCP-1) and IL-18 in a murine 
model of sepsis by A. baumannii, P. aeruginosa and E. coli [36]. Moreover, tamoxifen 
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has been shown to enhance the killing activity of macrophages and neutrophils 
against A. baumannii and E. coli in vitro [36]. Calcitriol, a bioactive form of vitamin 
D3 used to treat hypocalcemic conditions and renal osteodystrophy, has a similar 
mechanism of action which it has been described to enhance the killing activity 
of monocytes and macrophages towards P. aeruginosa [37]. Moreover, GTS-21, an 
anti-inflammatory drug, has presented therapeutic efficacy against P. aeruginosa in 
vivo by enhancing macrophage function via inhibiting the release of nuclear protein 
high mobility group box-1 (HMGB1) [39]. When GTS-21 is combined with M1 
muscarinic acetylcholine receptor agonist and α7n-acetylcholine receptor agonist 
against E. coli in vivo, the blood concentrations of pro-inflammatory cytokines 
TNF-α, IL-1β, and IL-6 were reduced significantly [38].
4. Repurposing drugs against MDR Gram-negative bacilli
There are currently multiple repurposing drugs in preclinical development for 
the treatment of infections by Gram-negative critical-priority pathogens. Few of 
them have been evaluated in early and late stage clinical trials. A summary of recent 
developments in repurposing drugs in vitro, in animal models and in clinical trials 
is presented below. The different clinical trials with repurposing drugs against these 
pathogens are listed in Table 2.
4.1 Acinetobacter baumannii
MDR A. baumannii is a well-recognized current global health threat that needs 
urgent effective solutions [1, 2]. Last-resort treatments such as colistin are no longer 
effective in an increasing number of cases, leading to a mortality rate of around 
35–60% in hospitalized patients with ventilator-associated pneumonia [54, 55]. 
The number of antibiotics approved by the FDA cannot keep up with the pace at 
which resistance is acquired by A. baumannii. The therapeutic potential of different 
repurposing drugs against A. baumannii has been tested in preclinical models, most 
of them in combination with polymyxins (colistin and polymyxin B) or its prodrug 
colistimethate sodium (CMS).
Repurposing 
drug
Clinical 
indication
Target 
bacteria
New clinical 
indication
Clinical trial 
phase
Clinical trial 
identifier
GTS-21 Inflammation E. coli Endotoxemia Interventional 
(Clinical trial)
NCT00783068
Sodium nitrite Acute cyanide 
poisoning
P. aeruginosa Cystic fibrosis 
(antimicrobial 
agent)
Phase I/II NCT02694393
Sodium nitrite Acute cyanide 
poisoning
P. aeruginosa Cystic fibrosis 
(biofilm 
disruptor)
Phase II NCT02295566
Gallium 
nitrate
Cancer-
associated 
hypercalcemia
P. aeruginosa Cystic fibrosis Phase II NCT02354859
Amitriptyline Depression P. aeruginosa Cystic fibrosis Phase II NCT00515229
Atorvastatin Hyper 
cholestremia
P. aeruginosa bronchiectasis 
and infection
Phase IV NCT01299194
Table 2. 
List of repurposing drugs under clinical trial development against Gram-negative critical-priority pathogens.
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4.1.1 Anticancer drugs
The antibacterial activity of anticancer drugs has been reported in vitro and 
in vivo non-vertebrate and vertebrate models by A. baumannii. Gallium nitrate 
has demonstrated an inhibitory effect on bacterial growth in a collection of 58 
MDR clinical isolates of A. baumannii in vitro [33]. This antibacterial activity is 
maintained in G. mellonella model. The administration of this drug alone and in 
combination with colistin, at concentrations mimicking the human therapeutic 
dose of gallium nitrate used for cancer patients (28 μM), significantly increased 
the survival of larvae after infection by A. baumannii [33]. When a vertebrate 
model was used such as murine models of acute and chronic lung infections 
by A. baumannii, gallium nitrate has reduced lung injury and bacterial loads in 
tissues [32]. Moreover, the combination of mitomycin C with tobramycin and 
ciprofloxacin together has increased in vitro the activity of this anticancer drug 
against MDR clinical isolates of A. baumannii [17]. Whereas, mitotane combined 
with polymyxin B against polymyxin B-resistant A. baumannii has presented 
synergy with polymyxin B, increasing the activity of polymyxin B in vitro and in 
murine model of burn wound infection by reducing the bacterial load in wounds 
[49]. Another group of anticancer drugs developed to combat breast cancer is the 
SERMs. Tamoxifen has been reported to exhibit activity in the immunocompetent 
and neutropenic murine model of peritoneal sepsis by ATCC 17978 strain by 
decreasing the bacterial loads in spleen, lungs and blood and increasing the mice 
survival [36]. Tamoxifen metabolites (N-desmethyltamoxifen, 4-hydroxytamoxi-
fen and endoxifen), produced after tamoxifen metabolizing by cytochrome P450 
[56], have presented antibacterial activity in vitro with MIC50 and MIC90 of 8 and 
16 mg/L, respectively, against a collection 100 MDR and pan-drug resistant (PDR) 
clinical isolates of A. baumannii [36].
4.1.2 Anthelmintic drugs
The potential activity of the anthelmintic drug has been also tested in vitro and 
in animal models by A. baumannii. Niclosamide, oxyclozanide, rafoxanide and iver-
mectin have been shown to potentiate the activity of colistin against clinical isolates 
of Col-R A. baumannii in vitro [30, 46–48, 57]. In the murine model of peritoneal 
sepsis by Col-R A. baumannii clinical isolate, rafoxanide plus CMS, a prodrug of 
colistin, compared with CMS alone increased mice survival to 53.8% and reduced 
bacterial loads in tissues and blood between 3 and 4 log10 cfu/g or mL, respectively 
[46]. Only, rafoxanide has exhibited antibacterial activity in monotherapy in this 
model of infection, but not in vitro [46].
4.1.3 Anti-inflammatory drugs
As is the case with anthelmintic drugs, anti-inflammatory drugs have demon-
strated antibacterial activity against A. baumannii in monotherapy and in combi-
nation with polmyxins in vitro. Glatiramer acetate has presented activity against 
reference strains and clinical bacteremic isolates of A. baumannii by disrupting 
the biofilm formation [42]. In addition, ebselen has presented antibacterial effect 
against A. baumannii by reducing their bacterial growth at MICs of 32 μM due 
to the inhibition of the siderephore TonB [51]. In combination with polymyxins, 
auranofin, a drug used for the treatment of rheumatoid arthritis, and celecoxib 
have exhibited synergy with polymyxin B and colistin against reference strains of 
A. baumannii respectively [19, 58].
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4.1.4 Other drugs
Other drugs with different modes of action and clinical indications have been 
evaluated as antibacterial agents against A. baumannii in monotherapy and in com-
bination with antibiotics. Simvastatin, used in the treatment of atherosclerotic car-
diovascular disease and hypercholesterolemia, has exhibited antibacterial activity 
in combination with sub-inhibitory concentrations of colistin against a collection of 
clinical isolates of A. baumannii, reducing the MIC of simvastatin from >256 mg/L 
to a range between 8 and 32 mg/L [59]. Two antiprotozoal drugs have been also 
evaluated in monotherapy and in combination with antibiotics. Robenidine has pre-
sented bactericidal activity alone and in combination with polymyxin B nanopep-
tide against reference strains of A. baumannii in vitro [60]. Pentamidine, in turn, has 
present synergy with novobiocin, a drug used for Gram-positive cocci infections, in 
vitro and in murine sepsis model by a reference strain of A. baumannii [29].
4.2 Pseudomonas aeruginosa
Pseudomonas aeruginosa is one of the most relevant pathogens causing human 
opportunistic infections in immunocompromised patients and severe nosocomial 
infections [61–63]. Indeed, P. aeruginosa is the top pathogen causing ventilator-
associated pneumonia and burn wound infections and is a major cause of nosoco-
mial bacteremia [62–64]. An MDR pattern is commonly observed in P. aeruginosa 
clinical isolates, raising the threat of difficult-to-treat infections [65–67]. These 
MDR isolates are generally susceptible to polymyxins and resistant to imipenem 
and ceftazidime [68]. New beta-lactamases inhibitors, combined with existing 
antibiotic families, such as ceftazidime/avibactam, ceftolozane/tazobactam, and 
imipenem/relebactam, against specific carbapenemases, have recently been devel-
oped [69]. Compared with A. baumannii, much more work has been done regarding 
the development of repurposing drugs for P. aeruginosa in preclinical and clinical 
stages.
4.2.1 Anticancer drugs
Different studies have been performed on P. aeruginosa to evaluate the antibac-
terial effect of anticancer drugs. Regarding SERM drugs, raloxifene attenuated 
in vitro and in C. elegans model the virulence of P. aeruginosa by binding to PhzB2 
which is involved in the production of pyocyanin [24]. Whereas, tamoxifen exhibit 
therapeutic efficacy in murine model of peritoneal sepsis by PAO1 strain by 
decreasing the bacterial loads in spleen, lungs and blood and increasing the mice 
survival [36]. In addition, cisplatin was found to inhibit microbial cells growth 
[17, 20] by the upregulation of the recA gene in P. aeruginosa [20]. 5-fluorouracil, 
in turn, has been used against a collection of 5850 mutants of the PA14 strain, 
revealing positive activity via the regulation of a large number of genes involved 
in QS and biofilm formation [41, 70]. In combination with antibiotics, two anti-
cancer drugs have been tested. Mitomycin C and mitotante in combination with 
tobramycin-ciprofloxacin [17] and polymyxin B [49], respectively, have shown 
synergy against MDR clinical and polymyxin-resistant isolates of P. aeruginosa, 
respectively. Finally, gallium nitrate is one the most studied and advanced cancer 
drug in clinical development against P. aeruginosa infection with promising data. 
Gallium nitrate has demonstrated an inhibitory effect on bacterial growth in P. 
aeruginosa at concentrations >3.13 μM in vitro [71, 72]; although the presence of 
pyoverdine and proteases in human serum reduce the efficacy of gallium nitrate 
against P. aeruginosa [73]. At non-bactericidal concentrations, gallium nitrate can 
11
Drugs Repurposing for Multi-Drug Resistant Bacterial Infections
DOI: http://dx.doi.org/10.5772/intechopen.93635
affect the production of virulence factors of P. aeruginosa [71, 74]. In murine mod-
els of acute and chronic lung infections by P. aeruginosa gallium nitrate has reduced 
the lung injury and bacterial loads in tissues of animals [71]. At clinical stage, a 
phase II clinical trial has been started in 2016 evaluating the capacity of gallium 
nitrate to improve the pulmonary function in 60 patients with cystic fibrosis by 
P. aeruginosa. The results of this trial showed that treatment with gallium nitrate 
increase the forced expiratory volume in these patients [75].
4.2.2 Anthelmintic drugs
The anthelmintic drugs niclosamide, oxyclozanide, rafoxanide and ivermectin 
have been shown to restore the activity of colistin against a collection of Col-R P. 
aeruginosa in vitro [46–48, 57]. Not only in combination with colistin, oxyclozanide 
has presented synergy with tobramycin to destruct the biofilm formation, permea-
bilizing the cells membrane and depolarizing the membrane potential of P. aerugi-
nosa strains resistant to tobramycin in vitro [28]. In the murine model of peritoneal 
sepsis by Col-R P. aeruginosa clinical isolate, rafoxanide plus CMS compared with 
CMS alone, increased mice survival to 73.3%, and reduced bacterial loads in tissues 
and blood between 3 and 5 log10 cfu/g or mL, respectively [46]. In monotherapy, 
niclosamide and rafoxanide have exhibited antibacterial activity against P. aerugi-
nosa. One in vitro study has indicated that niclosamide presented an anti-virulent 
effect against P. aeruginosa via the inhibition of QS and virulence genes, reducing 
elastase and pyocyanin levels [15]. Two additional in vivo studies have reported that 
niclosamide and rafoxanide showed therapeutic efficacy in G. mellonella larvae and 
in murine peritoneal sepsis models by a reference strain and Col-R clinical isolate of 
P. aeruginosa, respectively [15, 46]. Nevertheless, the absorption of niclosamide is 
lower. To increase this absorption, formulation of niclosamide under nanosuspen-
sion has been performed and showed lower toxicity in a rat lung infection model 
involving P. aeruginosa [14].
4.2.3 Anti-inflammatory and immunosuppressive drugs
Similar with A. baumannii, anti-inflammatory and immunosuppressive drugs 
have presented antibacterial activities in monotherapy and in combination with 
antibiotics against P. aeruginosa. The activity of glatiramer acetate against refer-
ence and clinical isolates of P. aeruginosa from chronic respiratory infections in 
cystic fibrosis patients has been observed by disruption of the biofilm formation 
[42]. With the same mechanism of action, ebselen and azathioprine has exhibited 
activity against P. aeruginosa [43, 45]. In turns, celecoxib and betamethasone have 
presented synergy with colistin, and with ceftazidime, erythromycin and ofloxacin 
against P. aeruginosa in vitro, respectively [19, 76]. Similarly, meloxicam has been 
reported to be in vitro active alone and in combination with the sub-MIC of tetracy-
cline, gentamicin, tobramycin, ciprofloxacin, ceftriaxone, ofloxacin, norfloxacin, 
ceftazidime against PAO1 strain, by inhibiting the biofilm formation [27]. Finally, 
GTS-21 has improved P. aeruginosa clearance in a murine model of ventilator-
associated pneumonia and reduced acute lung injury by enhancing macrophage 
function [39].
4.2.4 Antidepressive drugs
Regarding the antidepressive drugs, amitriptyline has reduced the inflammation 
in the lung of cystic fibrosis mice and prevented infection by P. aeruginosa [77]. At 
clinical stage, a phase II clinical trial evaluating the effect of amitriptyline on the 
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improvement of lung function in 18 patients with cystic fibrosis patients showed 
that amitriptyline improves the lung function by increasing the forced expiratory 
volume and weight of these patients [78, 79].
4.2.5 Other drugs
Other drugs with different modes of action and clinical indications have been 
evaluated as antibacterial agents against P. aeruginosa. Metformin has been reported 
to inhibit QS, biofilm formation, and swimming and twitching motilities of PAO1 
strain [21]. Calcitriol has enhanced the bactericidal activity against P. aeruginosa, 
modulating the activity of monocytes and macrophages to increase their bacterial 
killing [37]. Compared with A. baumannii, robenidine has been recently showed 
to present only synergy with polymyxin B nanpeptide against reference strains 
of P. aeruginosa in vitro [60]. Polymyxin B and colistin have been also combined 
with auronafin and simvastatin, respectively. Both drugs exhibited synergy with 
sub-inhibitory concentrations of polymyxin B and colistin against a collection of 
reference strains of P. aeruginosa, reducing the MIC of auronafin from >256 mg/L to 
0.125–0.5 mg/L and the MIC of simvastatin from >256 mg/L to 16–32 mg/L [58, 59]. 
At clinical stage, a phase IV trial determining the role of atorvastatin, another statin, 
in patients with bronchiectasis and infection with P. aeruginosa showed that atorvas-
tatin reduced systemic inflammation and improved quality of life of these patients 
[80, 81]. In addition, sodium nitrite, used for treatment of acute cyanide poisoning, 
has been shown in vitro to kill mucoid P. aeruginosa strains isolated from patients 
with cystic fibrosis, under anaerobic planktonic and biofilm conditions [82, 83]. Two 
early stage (I/II and II) clinical trials have been conducted to evaluate sodium nitrite 
as antimicrobial agent and as disrupter of biofilm formation in patients with cystic 
fibrosis by P. aeruginosa [84, 85]. The results from both studies have not yet published.
4.3 Enterobacterales
Escherichia coli and Klebsiella pneumoniae are of the most important pathogens 
in humans involved in different community and nosocomial infections, including 
bloodstream infections, urinary tract infections, intraabdominal infections and 
pneumonia [86–89]. The success of E. coli and K. pneumoniae as a community and 
nosocomial pathogens is attributed to their resistance to several antibiotic catego-
ries [86, 90]. Similar to P. aeruginosa the repurposing drugs developed today for E. 
coli and K. pneumoniae are in the preclinical and clinical stages of development.
4.3.1 Anticancer drugs
Anticancer drugs were developed against E. coli and K. pneumoniae in vitro and 
in animal models. Tamoxifen has been reported to exhibit activity in the immuno-
competent and neutropenic murine model of peritoneal sepsis by E. coli ATCC 25922 
strain by decreasing the bacterial loads in spleen, lungs and blood and increasing the 
mice survival [36]. Tamoxifen metabolites N-desmethyltamoxifen, 4-hydroxytamox-
ifen and endoxifen have presented antibacterial activity in vitro with MIC50 and 
MIC90 of 16 mg/L, against a 47 MDR clinical isolates of E. coli [36]. The activity of 
mitomycin C in monotherapy and in combination with tobramycin and ciprofloxacin 
together was increased against MDR clinical isolates of E. coli and K. pneumoniae in 
vitro [17, 18]. While, mitotane in combination with polymyxin B against polymyxin-
resistant K. pneumoniae increased the activity of polymyxin B in vitro [49].
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4.3.2 Anthelmintic drugs
Four anthelmintic drugs, niclosamide, oxyclozanide, rafoxanide and ivermectin 
were shown to present synergy with colistin against Col-R K. pneumoniae [30, 
46–48, 57]. Compared to Col-R isolates of A. baumannii and P. aeruginosa much 
lesser effect has been observed regarding the effect of these drugs in combination 
with colistin against Col-R isolates of K. pneumoniae. Additionally, in the murine 
model of peritoneal sepsis model by Col-R clinical isolate of K. pneumoniae, 
rafoxanide in monotherapy and in combination with CMS compared with control 
animals and with CMS alone, increased mouse survival to 50 and 67%, and reduced 
bacterial loads in tissues and blood between 2.5 and 3 log10 cfu/g or mL, and 2 and 3 
log10 cfu/g or mL, respectively [46].
4.3.3 Anti-inflammatory drugs
In the case of anti-inflammatory drugs, two drugs have presented syner-
gistic effect with antibiotics against E. coli and K. pneumoniae. The first one is 
celecoxib which has potentiated the activity of colistin against E. coli and K. 
pneumoniae [19]. In turn, betamethasone has presented synergy with ceftazi-
dime and ofloxacin against some isolates of E. coli [76]. Similar to A. baumannii 
and P. aeruginosa, glatiramer acetate has presented antibacterial effect against 
reference strains of E. coli by disrupting the biofilm formation [42]. Moreover, 
ebselen has been shown to present antibacterial effect against E. coli by reducing 
their bacterial growth at MICs <128 μM due to the inhibition of TonB [51], and 
azathioprine has exhibited anti-biofilm activity against E. coli through the inhi-
bition of WspR in vitro [43]. Finally, GTS-21 in combination with M1 muscarinic 
acetylcholine receptor agonist have been shown to reduce the mortality of mice 
in sepsis model by E. coli in 4 and 24 h [38]. At clinical stage, an interventional 
clinical trial on anti-inflammatory effects of oral administration of GTS-21 
on the inflammatory response in 7 patients with endotoxemia by LPS of E. coli 
showed that GTS-21 reduced the levels of proinflammatory cytokines in the 
plasma of these patients [91, 92].
4.3.4 Other drugs
Other drugs with different modes of action and clinical indications have 
been evaluated as antibacterial agents in monotherapy and in combined therapy 
with a large list of antibiotics against E. coli and K. pneumoniae in vitro and in 
animal models. Amoxapine has been reported to present therapeutic efficacy in 
an experimental murine model of respiratory infection by K. pneumoniae [93]. 
In addition, pentamidine in combination with different antibiotics ([novobio-
cin, erythromycin and rifampin] and [amikacin, tobramycin, tigecycline and 
rifampin]) has presented synergistic activity in vitro against different clinical 
isolates of E. coli harboring mcr-1 and K. pneumoniae producing carbapenemases, 
respectively [94]. In turn, robenidine has been recently showed to present only 
synergy with polymyxin B nanopeptide against reference strains of K. pneu-
moniae in vitro [60]. Finally, auronafin and simvastatin exhibited synergy with 
sub-inhibitory concentrations of polymyxin B and colistin against a collection 
of reference strains of E. coli and K. pneumoniae in vitro, reducing the MIC of 
auronafin from >256 mg/L to 0.25–1 mg/L and the MIC of simvastatin from 
>256 mg/L to 8–32 mg/L, respectively [58, 59].
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5. Conclusions
The retreat of the pharmaceutical sector from new antibiotic development has 
exacerbated the challenge of widespread resistance and signals a critical need for 
innovation. Repurposing drugs are an increasingly common practice in the phar-
maceutical industry where an already existing drug is applied in a new, previously 
unknown, way. This is advantageous mainly because these drugs are already cleared 
for human use and thus may skip straight to phase II clinical trials which presents 
considerably less risk and costs compared to developing new drugs. They could 
represent a promising approach to enrich the therapeutic arsenal against Gram-
negative critical-priority pathogens.
Some drugs indicated for human and veterinary use have been developed in 
combination with antibiotics; almost of them with polymyxins. They have yielded 
promising data in preclinical studies, specifically those with activity against biofilm 
formation and quorum sensing. However, additional relevant issues are required 
such as new formulations to increase their bioavailability and ADMET tests if the 
administration route is changed. Other drugs indicated for human use who have 
showed good activity against these pathogens in preclinical studies can be tested in 
advanced clinical trials. Early and late stages clinical trials with four repurposing 
drugs to treat cystic fibrosis and bronchiectasis by P. aeruginosa, and endotexemia 
by E. coli have provided promising results. Nevertheless, further clinical studies 
with extended clinical indications are needed to address the urgent demand for 
new treatments targeting infections caused by Gram-negative critical-priority 
pathogens.
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